HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$130.31
+1.31%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$130.81
From 52W high−0.66%
Volume976726.00
Market cap$14.79B
P/E (TTM)37.0x
P/S (TTM)8.9x
Div yield—
Key dataNov 4, 2026
Open
$130.81
From 52W high
−0.66%
Volume
976726.00
Market cap
$14.79B
ValuationView details →
P/E (Fwd)
13.1x
EV/EBITDA
23.3x
P/E (TTM)
37.0x
RSI (14)
68.8
MomentumView details →
1D Return
+1.31%
YTD Return
+90.53%
SummaryUpdated Jun 1, 2026
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a San Diego-based biopharma technology platform company founded in 1998 that went public in 2004. The company has evolved from a traditional biotechnology firm into a specialized drug delivery technology platform, leveraging its proprietary ENHANZE technology to enable pharmaceutical companies to convert intravenous biologics into more convenient subcutaneous formulations. Over the past decade, Halozyme has transformed its business model from primarily developing its own drugs to licensing its platform technology to major pharmaceutical partners, creating a highly scalable and profitable royalty-based revenue stream.
Similar companies
Latest newsMore news →
Halozyme announced that it will release its third-quarter 2026 financial and operating results on November 5, 2026, after market close, and host a conference call at 1:30 p.m. PT/4:30 p.m. ET.13d agoHalozyme expanded its ENHANZE collaboration and licensing agreement with ARGENX SE to cover eight targets, creating eligibility for additional milestone payments and royalties.28d ago